Researchers at Rensselaer Polytechnic Institute developed a regenerated cellulose (RC) membrane with peptide ligands that outperformed chromatography columns for mRNA purification, offering faster, higher‑yield removal of impurities and a potential pathway to lower mRNA manufacturing costs. The team has filed for patent protection and is seeking industry partners to commercialize the technology. Recipharm opened parenteral development and sterility labs in Bengaluru to accelerate injectable product development and cGMP transition, expanding CDMO capacity in a lower‑cost region. Together these advances address two choke points in mRNA and sterile biologics manufacturing: downstream purification efficiency and regional sterile development capacity.